Cases & Deals

Rgenix raises capital in $33 million Series B round

Clients Rgenix, Inc.

Jones Day represented Rgenix, Inc., a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, in connection with its issuance of $33 million of Series B Preferred Stock in a private placement to Novo A/S, Sofinnova Partners, Partnership Fund for New York City, Alexandria Venture Investments, and Conegliano Ventures LP.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.